ST Germain D J Co. Inc. Has $2.86 Million Position in Abbott Laboratories $ABT

ST Germain D J Co. Inc. reduced its holdings in Abbott Laboratories (NYSE:ABT) by 0.4% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 21,021 shares of the healthcare product maker’s stock after selling 80 shares during the period. ST Germain D J Co. Inc.’s holdings in Abbott Laboratories were worth $2,859,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of ABT. Hughes Financial Services LLC acquired a new position in Abbott Laboratories in the first quarter valued at approximately $27,000. Abound Financial LLC bought a new stake in Abbott Laboratories in the first quarter valued at approximately $28,000. Elequin Capital LP bought a new stake in Abbott Laboratories in the first quarter valued at approximately $30,000. JCIC Asset Management Inc. bought a new stake in Abbott Laboratories in the first quarter valued at approximately $32,000. Finally, Vision Financial Markets LLC bought a new stake in Abbott Laboratories in the first quarter valued at approximately $33,000. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CFO Philip P. Boudreau sold 5,550 shares of the stock in a transaction on Friday, August 8th. The shares were sold at an average price of $134.55, for a total transaction of $746,752.50. Following the completion of the transaction, the chief financial officer owned 51,003 shares in the company, valued at approximately $6,862,453.65. This represents a 9.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.46% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. Leerink Partnrs raised shares of Abbott Laboratories to a “hold” rating in a research note on Monday, June 16th. Morgan Stanley upped their target price on shares of Abbott Laboratories from $127.00 to $137.00 and gave the company an “equal weight” rating in a research note on Tuesday, July 15th. Jefferies Financial Group raised shares of Abbott Laboratories from a “hold” rating to a “buy” rating and upped their target price for the company from $143.00 to $145.00 in a research note on Friday, July 18th. Evercore ISI increased their price objective on shares of Abbott Laboratories from $140.00 to $145.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 8th. Finally, Mizuho increased their price objective on shares of Abbott Laboratories from $130.00 to $140.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 16th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $145.22.

Abbott Laboratories Stock Down 0.4%

Shares of ABT stock opened at $133.38 on Friday. Abbott Laboratories has a 12-month low of $110.86 and a 12-month high of $141.23. The firm has a fifty day moving average of $130.94 and a 200-day moving average of $131.14. The company has a market capitalization of $232.13 billion, a price-to-earnings ratio of 16.71, a P/E/G ratio of 2.54 and a beta of 0.69. The company has a quick ratio of 1.30, a current ratio of 1.82 and a debt-to-equity ratio of 0.25.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 EPS for the quarter, hitting the consensus estimate of $1.26. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The business had revenue of $11.14 billion during the quarter, compared to analysts’ expectations of $11.01 billion. During the same quarter in the prior year, the company posted $1.14 earnings per share. The firm’s revenue was up 7.4% on a year-over-year basis. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. As a group, equities research analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 17th. Investors of record on Wednesday, October 15th will be issued a dividend of $0.59 per share. The ex-dividend date is Wednesday, October 15th. This represents a $2.36 annualized dividend and a yield of 1.8%. Abbott Laboratories’s dividend payout ratio is presently 29.57%.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.